Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review

<table class="table-group" id="tab4"><tr><td><table class="table"><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr class="thead"><td align="left">Study</td><td align="center">Status</td><td align="center">Results</td><td align="center">NCT identifier</td></tr><tr><td class="thead-hr" colspan="4"><hr/></td></tr><tr><td align="left">MK2206 and AZD6244 in patients with advanced colorectal cancer</td><td align="center">Recruiting</td><td align="center">Pending</td><td align="center">NCT 01333475</td></tr><tr><td align="left">Phase 2 efficacy study of AZD6244 in colorectal cancer</td><td align="center">Completed</td><td align="center">Pending</td><td align="center">NCT00514761</td></tr><tr><td align="left">Selumetinib + irinotecan as 2nd-line patients with KRAS and BRAF mutation</td><td align="center">Recruiting</td><td align="center">Pending</td><td align="center">NCT01116271</td></tr><tr class="table-tr"><td colspan="4"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

Phase 2 clinical trials of selumetinib in colorectal cancer.

Chemotherapy Research and Practice

tab4

Table 4

Table 4: Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review 

Table 4 | Novel Drugs Targeting the Epidermal Growth Factor Receptor and Its Downstream Pathways in the Treatment of Colorectal Cancer: A Systematic Review 